Sebaceous carcinoma: evidence-based clinical practice guidelinesJoshua L. Owen, Michael K. Wong, Todd V. Cartee et al.|The Lancet Oncology|2019Cited by 204
Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathwaysLaura M. Rosenberg, Nancy L. Cho|Carcinogenesis|2018Cited by 48